Lymphatic filariasis is caused by the Brugia malayi parasite. Three new congeners of the depsipeptide WS9326A (1), WS9326C (2), WS9326D (3), and WS9326E (4), were isolated from Streptomyces sp. 9078 by using a B. malayi asparaginyl-tRNA synthetase (BmAsnRS) inhibition assay. WS9326D specifically inhibits the BmAsnRS, kills the adult B. malayi parasite, and does not exhibit significant general cytotoxicity to human hepatic cells, representing a new lead scaffold for antifilarial drug discovery.
the asparaginyl-tRNA synthetase (AsnRS) in B. malayi (i) is highly expressed in all stages of the parasite life cycle, (ii) is biochemically and structurally well characterized, and (iii) shows significant structural differences in comparison to human and other eukaryotic AARS. 5 In an effort to discover new antifilarial drug leads, we recently completed a high throughout screening campaign, targeting the BmAsnRS. Of the ∼73 000 extracts from a collection of 36 720 microbial strains screened, we identified 177 active strains. Previously, we reported the discovery of the tirandamycins (TAMs) from Streptomyces sp. 17944 and showed that TAM B was a potent and specific BmAsnRS inhibitor that efficiently killed the adult B. malayi parasite. 6 We now report bioassay-guided fractionation of another active strain, Streptomyces sp. 9078, leading to the discovery of three new congeners of the known depsipeptide WS9326A (1), 7 WS9326C (2), WS9326D (3), and WS9326E (4) (Figure 1 ). Importantly, 3, a moderate BmAsnRS inhibitor, efficiently kills the adult B. malayi parasite, representing another lead scaffold for antifilarial drug discovery.
The crude extract from a 9.6-L fermentation culture of Streptomyces sp. 9078 was subjected to sequential chromatography over SiO 2 and Sephadex LH-20 columns, followed by semipreparative HPLC over a C-18 column. Natural product isolation was guided by bioassay for inhibitory activity against the recombinant BmAsnRS, affording pure 1 (13.1 mg), 2 (5.2 mg), 3 (3.9 mg), and 4 (3.2 mg) as white powders, respectively [see Supporting Information (SI)]. Analysis of high resolution ESI-MS (HRESIMS) data and 1 H and 13 C NMR spectra of 1 and its triacetyl derivative 1a suggested 1 to be WS9326A, a depsipeptide that has been previously isolated from Streptomyces violaceoniger no. 9326. 7 The identity of 1 was unambigously confirmed by extensive 1D and 2D NMR analysis of 1 and 1a (Tables S1 and S2) , as well as comparison to the spectroscopic data reported previously.
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The molecular formula of 2 was determined to be C 53 Ser residue in 2a (Figure 1 ). This conclusion was further supported by key correlations observed in gHMBC, COSY, and NOESY experiments of 2a ( Figure 2A ). Since the absolute stereochemistry of 1 was known, 7 2, named as WS9326C, was assigned the same stereochemistry as that of 1 on the basis of its biosynthetic origin (Figure 1 ).
The molecular formula of 3 was determined to be C 47 H 59 N 5 O 10 by HRESIMS, affording an (Figure 1 ). This conclusion was further supported by key correlations observed in gHMBC, COSY, and NOESY experiments of 4 ( Figure 2C) . Hence, 4, named as WS9326E, could be viewed as a biosynthetic intermediate of 2 with the same absolute stereochemistry (Figure 1) .
Each of the purified compounds was reevaluated for their inhibitory activity against BmAsnRS using the recently reported nonradioactive assay. 8 This pretransfer editing assay exploits L-aspartate β-hydroxamate, a novel asparagine substrate mimic, to drive the enzymatic activity of AsnRS and maximize the production of inorganic phosphate that can be measured by its reaction with malachite green (SI). While 1 and 2 showed little activity at 100 μM, moderate inhibition against BmAsnRS was observed for 3 and 4 with apparent IC 50 s estimated to be 50 μM (for 3) and 75 μM (for 4), respectively ( Figure S1 ). We next tested 3 for its ability to kill adult B. malayi worms in vitro following the published procedure.
6 Live adult B. malayi worms were maintained in 6-well plates, and 3, varying from 10 nM to 50 μM, was added to selected wells with both albendazole (100 μM), a known LF drug, 3 and TAM B, the new LF drug lead we have discovered previously from S. sp. 17944, 6 as positive controls (SI). Remarkably, 3 kills the adult B. malayi worms rapidly within 24 h and can efficiently kill the adult worms within 10 days at concentrations as low as 10 nM ( Figure S2) ; worm death was unambiguously confirmed from simple paralysis by the modified MTT assay 6,9 ( Figure S3 , SI). Finally, 3 was evaluated using human HepG2 cells for general cytotoxicity, which was defined as >50% cell death at 24 h as measured by the MTT assay for mitochondrial activity, 9 and 3 was found to be nontoxic at concentration as high as 100 μM ( Figure S4, SI) .
Natural products remain the best sources of drugs and drug leads; however, natural products are underrepresented unfortunately in all small molecule libraries currently available. 10 Depsipeptide 1 was first isolated as a tachykinin antagonist from S. violaceoniger no. 9326 two decades ago.
Guided by the innovative high throughput screening targeting BmAsnRS, we now report that 3, a new congener of 1, is a novel BmAsnRS inhibitor, efficiently kills the adult B. malayi parasite, and does not exhibit significant general cytotoxicity to human hepatic cells. Therefore, 3 represents another new lead scaffold for antifilarial drug discovery. These findings, together with our early report of TAM B as a promising antifilarial drug lead, 6 underscore the great promise of our strategy in screening microbial natural products as BmAsnRS inhibitors for antifilarial drug discovery.
The fact that these leads can be produced in sufficient quantities by scale up microbial fermentation and that their biosynthetic machinery could be subjected to combinatorial biosynthetic strategies for titer improvement and structural diversity should greatly facilitate follow-up mechanistic and preclinical studies, thereby realistically developing these promising leads into potential clinical drugs.
